Grifols, S.A.
GRFS • Drug Manufacturers - General
$0.00
— 0.00 (0.00%)
EarningsLatest report: Mar 31, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Solid company profile with reasonable valuation support. The data suggests a balanced quality/value setup.
Market Cap
$6.16B
Growth
11.3%
Cash Flow
3/5
Trend
Mostly stable
Evidence
Stable or improving margins · 5.3%Positive revenue growth · 10.1%Positive free cash flow · 1.1Reasonable earnings multiple · 14.03Healthy liquidity · 2.51
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 7, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.00
Change0.00%
Market Cap$6.16B
52W Range7.25 - 11.14
Beta1.17
Gross Margin35.70%
Oper. Margin16.43%
Profit Margin5.34%
Debt/Eq1.66
Current Ratio2.51
Quick Ratio0.88
Revenue 5Y11.31%
Price$0.00
Change0.00%
Market Cap$6.16B
52W Range7.25 - 11.14
Beta1.17
Gross Margin35.70%
Oper. Margin16.43%
Profit Margin5.34%
Debt/Eq1.66
Current Ratio2.51
Quick Ratio0.88
Revenue 5Y11.31%
FCF 5Y7.02%
Volume688.21K
Avg Volume674.90K
EPS Surprise0.01
Investment DNA
How strong this company looks for long-term investors
75
out of 100
Business Quality
Margins, moat, returns
63/100
Financial Strength
Debt, cash, stability
51/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
91/100
Why this score▼
Stable or improving margins · 5.3%Positive revenue growth · 10.1%Positive free cash flow · 1.1Reasonable earnings multiple · 14.03Healthy liquidity · 2.51
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 8 analyst votes · 2026-09-04
63/100
Neutral
Bullish
4
Hold
2
Bearish
2
🧾
No insider activity
No recent insider transactions available.